{"product_id":"ipsen-business-model-canvas","title":"Ipsen Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIpsen's Business Model: A Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious about how Ipsen achieves its market dominance? Our Business Model Canvas breaks down their customer relationships, revenue streams, and key resources, offering a clear view of their strategic genius.  For anyone aiming to replicate or adapt successful business frameworks, this is an essential tool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances for Pipeline Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIpsen actively pursues global licensing agreements to bolster its drug pipeline, securing rights to promising new treatments. This approach is crucial for swiftly growing its portfolio, especially within its key therapeutic focus areas.\u003c\/p\u003e\n\u003cp\u003eThis strategic alliance model allows Ipsen to access cutting-edge science and technology, accelerating its development timelines. For instance, in 2024, Ipsen continued to explore opportunities in areas like Antibody Drug Conjugates (ADCs) and T-cell engagers, aiming to integrate novel modalities into its R\u0026amp;D framework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Biotech Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIpsen heavily relies on external innovation, actively partnering with academic institutions and biotech firms to access cutting-edge science. This strategy allows them to tap into specialized expertise, accelerating the discovery and development of novel therapies.  For instance, in 2024, Ipsen continued to expand its pipeline through such collaborations, aiming to de-risk and diversify its research and development portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMergers and Acquisitions for Portfolio Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIpsen's strategy heavily relies on mergers and acquisitions to fuel portfolio expansion, particularly in specialty care areas.  This approach allows them to integrate innovative assets and solidify their market position.\u003c\/p\u003e\n\u003cp\u003eSignificant acquisitions like Albireo and Epizyme in recent years have been pivotal. These moves specifically targeted and strengthened Ipsen's rare disease and oncology segments, bringing in valuable products such as Bylvay and Tazverik.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Ipsen completed the acquisition of Albireo Pharma for approximately $972 million, a move that significantly bolstered its rare liver disease portfolio. This acquisition, along with others, underscores their commitment to inorganic growth and strategic market penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research and Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIpsen strategically collaborates with Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) to enhance its research and development processes and navigate the complexities of drug manufacturing.\u003c\/p\u003e\n\u003cp\u003eThese external partnerships provide Ipsen with access to specialized expertise and advanced technologies, allowing the company to accelerate drug discovery and development timelines. By outsourcing certain functions, Ipsen can concentrate its internal resources on core strategic initiatives, such as identifying novel therapeutic targets and advancing late-stage clinical trials.\u003c\/p\u003e\n\u003cp\u003eFor instance, in 2024, pharmaceutical companies globally continued to increase their reliance on CROs, with the market projected to reach over $70 billion by 2025, indicating a strong trend in outsourcing R\u0026amp;D activities. Ipsen's engagement with these partners is crucial for maintaining a competitive edge in a rapidly evolving biopharmaceutical landscape.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccess to Specialized Expertise:\u003c\/strong\u003e CROs and CDMOs offer niche skills in areas like preclinical testing, clinical trial management, and complex biologics manufacturing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCost and Time Efficiency:\u003c\/strong\u003e Outsourcing allows Ipsen to avoid significant capital investment in specialized facilities and equipment, and can speed up development cycles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eScalability and Flexibility:\u003c\/strong\u003e Partnerships enable Ipsen to scale its R\u0026amp;D and manufacturing capabilities up or down as needed, responding effectively to project demands.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFocus on Core Competencies:\u003c\/strong\u003e By delegating non-core activities, Ipsen's internal teams can dedicate more time to strategic decision-making and innovation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Distribution Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIpsen leverages commercialization and distribution partnerships to extend its global reach, ensuring its medicines are accessible in over 100 countries. These collaborations are vital for market penetration and patient access to innovative therapies.\u003c\/p\u003e\n\u003cp\u003eThese strategic alliances often involve shared financial commitments and risk-sharing models, aligning partner incentives with Ipsen's commercial objectives. For instance, in 2024, Ipsen continued to expand its presence in emerging markets through such agreements, aiming to capture new patient populations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Market Access:\u003c\/strong\u003e Partnerships enable Ipsen to navigate diverse regulatory landscapes and distribution networks efficiently.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRisk Mitigation:\u003c\/strong\u003e Shared commercialization efforts can reduce financial exposure and accelerate market entry.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Enhancement:\u003c\/strong\u003e Collaborations contribute to increased sales volumes and broader therapeutic area coverage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Alignment:\u003c\/strong\u003e Joint ventures and licensing agreements foster mutual growth and market development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIpsen's Strategic Partnerships Drive Pipeline \u0026amp; Global Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIpsen's key partnerships are vital for expanding its pipeline and market reach, focusing on licensing agreements with biotech firms and academic institutions to access novel therapies, particularly in oncology and rare diseases.\u003c\/p\u003e\n\u003cp\u003eThe company actively engages with Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) to streamline R\u0026amp;D and manufacturing, a trend supported by the global CRO market projected to exceed $70 billion by 2025.\u003c\/p\u003e\n\u003cp\u003eCommercialization and distribution alliances are crucial for global market penetration, ensuring Ipsen's medicines reach patients in over 100 countries, with strategic collaborations in emerging markets showing significant growth in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eStrategic Importance\u003c\/th\u003e\n\u003cth\u003eExample\/Trend (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech Firms \u0026amp; Academia\u003c\/td\u003e\n\u003ctd\u003ePipeline Expansion, Novel Modalities (ADCs, T-cell engagers)\u003c\/td\u003e\n\u003ctd\u003eAccess to cutting-edge science, de-risking R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs \u0026amp; CDMOs\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Acceleration, Manufacturing Efficiency\u003c\/td\u003e\n\u003ctd\u003eOutsourcing specialized functions, cost\/time efficiency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization Partners\u003c\/td\u003e\n\u003ctd\u003eGlobal Market Access, Risk Mitigation\u003c\/td\u003e\n\u003ctd\u003eExpanding reach in 100+ countries, emerging market growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA detailed breakdown of Ipsen's strategy, outlining its key customer segments, value propositions, and revenue streams within the pharmaceutical industry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Ipsen Business Model Canvas simplifies complex strategies, alleviating the pain of convoluted planning by offering a clear, visual representation of key business elements.\u003c\/p\u003e\n\u003cp\u003eIt acts as a pain point reliever by providing a structured framework that streamlines the identification and articulation of value propositions, customer segments, and revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development of Novel Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIpsen's core strength lies in its dedicated research and development of innovative medicines.  The company strategically focuses its R\u0026amp;D on Oncology, Neuroscience, and Rare Diseases, aiming to bring groundbreaking treatments to patients.\u003c\/p\u003e\n\u003cp\u003eThis commitment translates into a robust pipeline, encompassing everything from early-stage preclinical research to late-stage clinical trials.  In 2023, Ipsen invested €1.1 billion in R\u0026amp;D, underscoring its dedication to advancing scientific discovery and expanding its therapeutic offerings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIpsen's core manufacturing activities focus on producing its prescription drugs, a critical step to guarantee consistent quality and availability for patients. This encompasses intricate production processes and the management of a sophisticated global supply chain, ensuring efficient delivery of medicines across diverse international markets.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Ipsen continued to invest in its manufacturing capabilities, aiming to enhance capacity and operational efficiency. The company's commitment to maintaining high pharmaceutical standards and optimizing logistics is paramount for ensuring uninterrupted patient access to its therapeutic solutions worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Marketing of Specialty Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIpsen focuses on the global commercialization and marketing of its specialty drugs, ensuring strategic product launches and sustained promotional efforts for its portfolio. This includes the recent launches of Iqirvo and Bylvay, alongside continued support for established brands like Cabometyx and Somatuline, which are key drivers of revenue. \u003c\/p\u003e\n\u003cp\u003eIn 2023, Ipsen reported significant sales for its key products, with Cabometyx achieving €1.1 billion and Somatuline reaching €960 million, underscoring the importance of effective commercial execution in driving market penetration and sales growth for these vital therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIpsen's key activities include meticulously navigating intricate regulatory pathways to gain approvals for its innovative medicines and new therapeutic indications from health authorities worldwide. This ensures their treatments meet stringent safety and efficacy standards before reaching patients.\u003c\/p\u003e\n\u003cp\u003eFurthermore, a crucial focus is placed on developing robust market access strategies. This involves proactive engagement with payers and diverse healthcare systems to negotiate favorable reimbursement terms and guarantee widespread patient accessibility to Ipsen's specialized care offerings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Approvals:\u003c\/strong\u003e Securing marketing authorizations from agencies like the FDA and EMA for new drug applications and label expansions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access Strategies:\u003c\/strong\u003e Engaging with national health technology assessment bodies and reimbursement authorities to facilitate patient access.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Compliance:\u003c\/strong\u003e Maintaining adherence to evolving pharmaceutical regulations across different geographic markets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePost-Market Surveillance:\u003c\/strong\u003e Managing ongoing regulatory requirements and pharmacovigilance activities after product launch.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Development and External Innovation Sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIpsen actively pursues external innovation through strategic business development, focusing on in-licensing and acquisitions to enhance its drug pipeline. This is crucial for introducing novel therapeutic modalities and assets that target significant unmet medical needs, driving the company's growth.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Ipsen continued to invest in external innovation, a cornerstone of its strategy to diversify and strengthen its portfolio. For instance, the company completed several key transactions aimed at acquiring promising early-stage assets and technologies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Enhancement:\u003c\/strong\u003e Sourcing external innovation directly contributes to replenishing and diversifying Ipsen's research and development pipeline.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAddressing Unmet Needs:\u003c\/strong\u003e This strategy is vital for bringing in new therapeutic modalities and assets to tackle high unmet medical needs across various disease areas.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth Driver:\u003c\/strong\u003e External innovation sourcing is a core component of Ipsen's overall growth strategy, ensuring long-term competitiveness and market position.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Impact: R\u0026amp;D, Manufacturing, and Commercialization Drive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIpsen's key activities are centered around its robust research and development efforts, focusing on Oncology, Neuroscience, and Rare Diseases to create innovative treatments. The company actively manages its manufacturing processes to ensure the quality and availability of its prescription drugs globally, with continued investment in 2024 to enhance these capabilities. Furthermore, Ipsen excels in the global commercialization and marketing of its specialty drugs, supported by strategic product launches and ongoing promotional activities for key revenue drivers.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Ipsen Business Model Canvas preview you are viewing is the actual, complete document that will be delivered upon purchase. This means you'll receive the exact same structured and professionally formatted content you see now, ready for immediate use. There are no alterations or missing sections between this preview and the final download, ensuring you get precisely what you expect.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611304903033,"sku":"ipsen-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ipsen-business-model-canvas.png?v=1754754921","url":"https:\/\/growthsharematrix.com\/products\/ipsen-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}